Paul Berns

Mr. Paul L.
Berns is an Independent Non-Executive Director at Kardigan, Inc., an Executive Chairman at Ollin Biosciences, Inc., a Chairman at Human Immunology Biosciences, Inc., an Executive Chairman at Neumora Therapeutics, Inc., a Managing Director at ARCH Venture Partners LLC, a Chairman at Happy Ai Software, Inc. and an Executive Chairman at Tenvie Therapeutics, Inc. He is on the Board of Directors at Kardigan, Inc., Elephas Biosciences Corp., EQRx International, Inc., Happy Health, Inc., Epirium Bio, Inc., Areteia Therapeutics, Inc., Mirador Therapeutics, Inc., RhyGaze AG and Salma Health, Inc. Mr. Berns was previously employed as a Lead Independent Director by Metsera, Inc., a Chairman by HIBio, Inc., an Independent Director by EQRx, Inc., a Chief Executive Officer by BlackThorn Therapeutics, Inc., an Independent Director by Unity Biotechnology, Inc., an Independent Director by Menlo Therapeutics, Inc., an Independent Director by Novelos Therapeutics, Inc., a Chairman by Cellectar Biosciences, Inc., a Chairman, President & Chief Executive Officer by Anacor Pharmaceuticals LLC, an Independent Director by Jazz Pharmaceuticals Plc, a President, Chief Executive Officer & Director by Allos Therapeutics, Inc., an Independent Director by XenoPort, Inc., a President, Chief Executive Officer & Director by Bone Care International, Inc., a VP & General Manager-Immunology & Oncology by Abbott Laboratories, a Vice President-Marketing by BASF SA, and a Vice President-Marketing by Knoll AG.
He also served on the board at VYNE Therapeutics, Inc., Mc2 Therapeutics AS, Jazz Pharmaceuticals, Inc. and Ren Pharmaceuticals, Inc. He received his undergraduate degree from the University of Wisconsin.